Procrit

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., University of Louisville, M.D. Anderson Cancer Center

Conditions

Acute Myelogenous LeukemiaAnemiaCancerLeukemiaMyelodysplastic Syndrome

Phase 2

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

TerminatedNCT00210626

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Anemia

Start: 2005-08-31End: 2008-06-30Updated: 2014-04-21

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

WithdrawnNCT00624312

University of LouisvilleCancer

Start: 2008-02-29End: 2010-01-31Updated: 2021-08-06

Phase 3

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

CompletedNCT00656448

M.D. Anderson Cancer CenterAcute Myelogenous Leukemia, Leukemia, Myelodysplastic Syndrome

Start: 2008-03-31End: 2013-06-30Updated: 2018-05-30